At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 172 enrolled
Drug / intervention
Prexasertibdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2 Study of Prexasertib in Platinum-Resistant or Refractory Recurrent Ovarian Cancer
In Brief
A Phase 2 clinical trial evaluating Prexasertib for Ovarian Cancer. Completed, enrolled 172 participants across 46 sites in 8 countries.
Detailed Summary
The purpose of this study is to evaluate the efficacy and safety of prexasertib in women with platinum-resistant or refractory recurrent ovarian cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOvarian Cancer
CountriesAustralia, Belgium, Israel, Italy, South Korea, Spain, United Kingdom, United States
Collaborators--
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedJan 2018
Enrollment StartApr 2018
Primary CompletionJun 2019
Study CompletionOct 2020
TodayJul 2026
First PostedJan 29, 2018
Enrollment StartApr 10, 2018
Primary CompletionJun 3, 2019
Study CompletionOct 3, 2020
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 8.4 years ago
Interventions
Prexasertibdrug
Administered IV